copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
AstraZeneca | Cafepharma AstraZeneca’s Imfinzi can now be used to treat patients with gastric and gastroesophageal junction cancers as part of a chemotherapy combination, adding another indication for the blockbuster PD-L1 inhibitor
AstraZenecas latest amyloidosis pact with Neurimmune could reach $780M . . . Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to pick up a second asset The latest licensing deal involves NI009, a preclinical monoclonal antibody that targets lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis In return for the exclusive rights, AstraZeneca’s Alexion
Imfinzi | Cafepharma AstraZeneca’s Imfinzi can now be used to treat patients with gastric and gastroesophageal junction cancers as part of a chemotherapy combination, adding another indication for the blockbuster PD-L1 inhibitor
light chain amyloidosis | Cafepharma Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to pick up a second asset The latest licensing deal involves NI009, a preclinical monoclonal antibody that targets lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis
baxdrostat | Cafepharma AstraZeneca's baxdrostat has hit the mark in another phase 3 trial involving people who struggle to control their blood pressure with current therapies, keeping the would-be blockbuster on track for regulatory filings this year
Fasenra | Cafepharma AstraZeneca's Fasenra (benralizumab) has recently been approved by the FDA for treating severe asthma in children aged 6 to 11 with the eosinophilic phenotype A phase III clinical trial is now underway to test the effectiveness of Fasenra in COPD
Cafepharma News Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends